Registration Information for Herantis Pharma’s Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout

Herantis Pharma Plc
Company release 11 Sep 2020 at 9:00 am

Herantis Pharma Plc (“Herantis” or “Company”) today announces the registration information for the upcoming webinar that will highlight more details on CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months (link to press release).

Event Details:

CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months

Date and Time: September 15, 2020 at 15:00 – 16:00 CET
Presenters: Craig Cook CEO, Antti Vuolanto COO, Henri Huttunen CSO

The webinar will commence with a presentation by the Company, followed by a live Q&A session.

To join the Webinar: Register for Webinar here

About the presenters:

Craig Cook, CEO

A medical doctor with an MBA from the London Business School, Dr. Cook brings more than 20 years of experience in the international pharmaceutical and biotechnology sectors.  His career has realised increasingly senior roles in drug development and commercialization at major life science companies such as Eli Lilly, Johnson & Johnson, Novartis and EMD Serono, as well as entrepreneurial success in several healthcare initiatives. Most recently Dr. Cook was CEO of Midatech Pharma PLC a dual Nasdaq and AIM listed biotech company, before deciding to join Herantis Pharma.  He has worked across several therapeutic areas including neurology, immunology, and oncology.

Antti Vuolanto, COO

Antti Vuolanto, DSc, joined Herantis Pharma Plc in February 2018. He has vast experience in biological drug development, gene therapy, and in-vitro diagnostics. Previously he has served as COO at Valo Therapeutics, as Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that was merged with Targovax in 2015. He has also held senior management positions at other biotech companies. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.

Henri Huttunen, CSO

Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO until February 2010. Dr. Huttunen is currently the Chief Scientific Officer of Herantis, and has also served as member of the Board of Directors until April 2014. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr. Huttunen has a PhD in biochemistry from the University of Helsinki and more than 20 years of experience in neuroscience research.

For more information, please contact:
Julie Silber/Gabriela Urquilla

JG-IR

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

About CDNF

Cerebral Dopamine Neurotrophic Factor (CDNF) is a promising innovative drug candidate for the treatment of neurodegenerative diseases.  This unique compound is a member of a novel family of unconventional neurotrophic factors which is structurally and mechanistically very distinct from all known neurotrophic factors. Specifically, CDNF acts via a multimodal mechanism that involves modulation of endoplasmic reticulum (ER) stress, a-synuclein aggregation and toxicity and reduced neuroinflammation. CDNF is patented internationally by Herantis.

In preclinical studies it has definitively been shown to be safe and effective. In particular, it protects and regenerates dopamine-generating cells in the midbrain, suggesting potential for disease modification of Parkinson’s disease.  It has shown efficacy in both motor and non-motor symptoms in rodent and primate models of Parkinson’s disease. 

CDNF has entered the clinic where its profile is being evaluated for safety and efficacy. A Phase I-II study was successfully completed which has established safety of the product and preliminary indications of efficacy in patients.  

About Parkinson’s disease

Parkinson’s disease (PD) is a slowly progressing, incurable neurodegenerative disease caused by the loss of dopaminergic neurons in the midbrain. Common first symptoms of the disease include tremors, rigidity, and slowness of movement. While the motor symptoms can be treated with medication, the progression of the disease cannot be prevented. The benefits of medication may be lost with disease progression or their side effects can become unmanageable. The progressing disease is also associated with non-motor symptoms such as sleep problems, depression, and anxiety, which are not alleviated by current Parkinson’s drugs. It is estimated that 7-10 million people worldwide suffer from Parkinson’s disease.

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

Attachment